We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

CombiMatrix Granted Key Nanotechnology Patent

CombiMatrix Granted Key Nanotechnology Patent

CombiMatrix Granted Key Nanotechnology Patent

CombiMatrix Granted Key Nanotechnology Patent

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CombiMatrix Granted Key Nanotechnology Patent "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Acacia Research Corporation has announced that its CombiMatrix group was granted a key patent in Europe (EP1185363B1), titled "Self-Assembling Arrays" by the European Patent Office.

This European Patent was registered throughout the European Union in Germany, France, Spain, Great Britain, and Italy, and the opposition period has passed.

A corresponding U.S. patent is pending in the U.S. Patent and Trademark Office and is moving through the process.

The European patent claims both self-assembled arrays and a method for making self-assembled arrays on electrode arrays with self-assembled antibodies.

This microarray configuration is useful for arraying proteins specifically antibodies. The technology is designed to enable products such as multiplexed immunoassays, monitoring of biowarfare and terrorist agents, and general protein analysis tools.

"CombiMatrix's intellectual property strategy is designed to provide freedom to operate for CombiMatrix products as well as to establish strong barriers to protect the unique aspects and commercial advantages of our electrochemical synthesis and detection technologies," said Dr. Jeff Oster, Senior Vice President, Legal at CombiMatrix.

"In this case, we decided to wait the nine months after publication of the grant to let the opposition period expire before announcing."